Loading...
LKFT logo

Lakefront Biotherapeutics NVNasdaqGS:LKFT Aktienübersicht

Marktkapitalisierung US$1.8b
Aktienkurs
US$27.67
US$34.99
20.9% unterbewertet intrinsischer Abschlag
1Y-4.5%
7D4.0%
1D
Wert des Portfolios
​
Siehe

Lakefront Biotherapeutics NV

NasdaqGS:LKFT Lagerbericht

Marktkapitalisierung: US$1.8b

Lakefront Biotherapeutics (LKFT) Aktienübersicht

Lakefront Biotherapeutics NV, ein Biotechnologieunternehmen, entwickelt Medikamente mit Schwerpunkt Onkologie und Immunologie, hauptsächlich in den Vereinigten Staaten und Europa. Mehr Details

LKFT grundlegende Analyse
Schneeflocken-Punktzahl
Bewertung5/6
Künftiges Wachstum0/6
Vergangene Leistung2/6
Finanzielle Gesundheit6/6
Dividenden0/6

Belohnungen

28.7% unter unserer Schätzung des beizulegenden Zeitwerts gehandelt

In diesem Jahr profitabel geworden

Im Vergleich zu Wettbewerbern und der Branche gut bewertet

Risikoanalyse

Die Erträge werden in den nächsten 3 Jahren voraussichtlich um durchschnittlich 43.1% pro Jahr sinken.

Große einmalige Posten, die sich auf die Finanzergebnisse auswirken


LKFT Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

View all narratives

Lakefront Biotherapeutics NV Wettbewerber

Preisentwicklung & Leistung

Zusammenfassung der Höchst- und Tiefststände sowie der Veränderungen der Aktienkurse für Lakefront Biotherapeutics
Historische Aktienkurse
Aktueller Aktienkurs€27.67
52-Wochen-Hoch€37.78
52-Wochen-Tief€26.42
Beta0.11
1 Monat Veränderung-3.25%
3 Monate Veränderung-18.67%
1 Jahr Veränderung-4.49%
3 Jahre Veränderung-34.34%
5 Jahre Veränderung-62.52%
Veränderung seit IPO252.48%

Aktuelle Nachrichten und Updates

Seeking Alpha • Feb 26

Galapagos FY25: Profits Not Built On Product

Summary Galapagos NV (GLPG) reported FY25 GAAP EPS of €4.87 and €1.11B revenue, driven by one-time accounting from Gilead collaboration amendments. GLPG’s profitability is structurally accounting-driven, not reflective of recurring operational strength; underlying business is shrinking with cell therapy exit and pipeline narrowing to TYK2. Management guides for 2026 cash-flow neutrality, €2.78–2.88B year-end cash, and a shift toward business development and capital allocation over internal R&D. GLPG trades at a negative enterprise value, with investors valuing only its cash pile and deeply discounting future execution and strategic repositioning. Read the full article on Seeking Alpha

Recent updates

Seeking Alpha • Feb 26

Galapagos FY25: Profits Not Built On Product

Summary Galapagos NV (GLPG) reported FY25 GAAP EPS of €4.87 and €1.11B revenue, driven by one-time accounting from Gilead collaboration amendments. GLPG’s profitability is structurally accounting-driven, not reflective of recurring operational strength; underlying business is shrinking with cell therapy exit and pipeline narrowing to TYK2. Management guides for 2026 cash-flow neutrality, €2.78–2.88B year-end cash, and a shift toward business development and capital allocation over internal R&D. GLPG trades at a negative enterprise value, with investors valuing only its cash pile and deeply discounting future execution and strategic repositioning. Read the full article on Seeking Alpha
Seeking Alpha • Feb 20

Disount To Net Cash For A Promising CAR-T Company

Summary Galapagos NV announced a strategic split with Gilead Sciences, creating 'New Galapagos' and 'SpinCo', aiming to unlock shareholder value and reduce staffing by 40%. 'New Galapagos' will focus on cell therapies and small molecules, while 'SpinCo' will target oncology, immunology, and virology with €2.45 billion in capital. Despite an 18% share decline post-announcement, the split offers deep value and potential catalysts, though risks include governance concerns, competitive CAR-T space, and executional challenges. Valuation suggests a 52% upside, with 'New Galapagos' holding €500 million in cash and 'SpinCo' poised for M&A activities in a favorable biotech environment. Read the full article on Seeking Alpha
Seeking Alpha • Dec 14

Galapagos Struggles To Carve A Path In A Crowded CAR-T Therapy Market

Summary Galapagos' CAR-T therapy GLPG5101 shows promising efficacy but has limited durability data and small patient samples compared to Yescarta. Phase 1 safety concerns have improved in Phase 2, though long-term safety data remains incomplete. Financially, Galapagos boasts robust cash reserves and a runway extending beyond 2027, but its burn rate is likely to increase. The company’s pivot to CAR-T is strategically ambitious but enters a highly competitive market with entrenched players like Gilead and Novartis. Galapagos remains a "sell" due to underwhelming differentiation, cash inefficiencies, and reliance on external pressures to drive strategic change. Read the full article on Seeking Alpha
Seeking Alpha • Aug 23

Galapagos: CAR-T Biotech To Change Landscape With GLPG5101 And Beyond

Summary Galapagos NV achieved positive results from its European phase 1/2 ATLANTA-1 study using GLPG5101 for patients with relapsed/refractory NHL; phase 1 portion with 87.5% ORR and phase 2 portion with 93.3% ORR. The global non-Hodgkin Lymphoma market is expected to reach $16 billion by 2029; on average, between 30% to 40% of NHL patients have relapsed/refractory disease. IND clearance of U.S. phase 1/2 ATLANTA-1 study using GLPG5101 for patients with relapsed/refractory NHL achieved; this trial could speed up enrollment and further establish efficacy with newly added patients. GLPG5201 and GLPG5301 are two other candidates in the pipeline, which are being developed to target patients with relapsed/refractory chronic lymphocytic leukemia and relapsed/refractory Multiple Myeloma patients, respectively. Read the full article on Seeking Alpha
Seeking Alpha • Mar 07

Galapagos: Pipeline Still Progressing Despite Financial Volatility

Summary Galapagos has managed to curtail its R&D and G&A expenses, demonstrating efficient cost management. The company has strategically focused on oncology and immunology, sectors with high unmet medical needs and market impact potential. Galapagos is investing in CAR-T cell therapies, with promising early data indicating progress in its unique manufacturing platform. Read the full article on Seeking Alpha
Seeking Alpha • Oct 10

Galapagos: Trading At Discount To Cash With A Fast-Growing Marketed Product

Summary Galapagos has had a new CEO since April 2022. The company's new strategy is taking shape with some research programs scrapped and small assets acquired. Jyseleca is growing rapidly and has a way to go. Meanwhile, Galapagos trades at a sizeable discount to cash. Galapagos NV (GLPG) is a biotech with a market cap of $2.9 billion that's been around for a while with a storied history. It managed to raise a lot of money in the past and currently has a bunch of early-stage assets to show for all its investments in R&D over the years. It was incorporated in 1999 and is headquartered in Mechelen, Belgium. I like this biotech at $43.55 because it holds billions of dollars of cash (over $4 billion) and virtually no debt. There's cash burn, but that's becoming more manageable as the company now has an asset that's being marketed in JYSELECA. For now, operating cash burn is at a run-rate of around ~$400/year. Paul Stoffels took over as CEO in April 2022. The new management is contemplating how to run the business best, but meanwhile executed two small acquisitions (that increased cash burn a bit for the year). Galapagos strategic review (Galapagos) Stoffels commented on the strategic review as follows on the recent earnings call (emphasis mine): Let me say, we have the internal review where we look internally but we have also a very extensive external review on what business opportunities we can bring in at the moment. So it goes in parallel, we're looking strategically, what are the assets and the portfolio prioritization internally as well as looking at additional potential short-term acquisitions as the market now is very -- looking for very -- many biotech companies are looking for partnerships now and it's a great opportunity for us to evaluate that. We will mainly focus on -- at the moment on oncology and -- in oncology and inflammation. In the past, we have said we are looking at select infectious disease opportunities if they would be there. But oncology and inflammation will be the key. And we'll evaluate internally our fibrosis assets and see whether there are still compounds which are valuable and word in the acquisition -- in capital allocation. Where we are is like, let's say, we are in the middle of the review as I'm -- we are in the middle of the review and one-by-one, this is the first reporting to you. And on the Capital Markets Day, we'll be able to give you further insights on long-term strategy, both on oncology and inflammation, other assets in the company as hopefully by then but maybe not yet next opportunities in acquisitions or licensing. Meanwhile, Jyseleca is performing quite well: Jyseleca growth (Galapagos) The company expects to top out at ~$500 million in annual sales in Europe. That's still years away, but it will still be a powerful force in bringing operating cash burn down. With the market cap well below the net cash on the balance sheet and this growing revenue stream, and no debt, I think the shares are definitely on the cheap side. Management will need to make some disastrous decisions or be very unlucky to wreck future returns from this position and share price. There are option angles that I think are worth contemplating. For a long time, Galapagos has been a huge bag of cash with some cash burn and not a lot happening. Large amounts of cash are volatility dampening and its options market has relatively muted implied volatility. Its implied volatility is still higher than a biotech index like the iShares Biotechnology ETF (IBB), but not by that much. See SPDR S&P Biotech ETF (XBI) below: Straddle XBI (optionstrat)
Seeking Alpha • Oct 03

EMA panel approves amending label for Galapagos' Jyseleca on testicular function effects

Belgian pharmaceutical firm Galapagos (NASDAQ:GLPG) on Monday said the European Union's human medicines committee had recommended amending the label of its inhibitor Jyseleca to remove a warning regarding its effect on testicular function. The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion on GLPG's type 2 variation application, GLPG said in a statement. Jyseleca is indicated for the treatment of patients with inflammatory bowel disease and rheumatic conditions. The variation application was supported by interim data from two ongoing studies called MANTA and MANTA-RAy, GLPG said. The CHMP concluded that the interim data did not suggest that Jyseleca had an effect on the testicular function of patients. Following the CHMP's opinion, Jyseleca's label will be amended to remove the language in the section of special warnings and precautions about the potential effect of the drug on sperm production and male fertility. U.S.-listed shares of GLPG earlier closed +0.5% at $42.85.
Seeking Alpha • Jul 25

Galapagos stock dips after Jefferies slashes rating citing challenges ahead

Galapagos (NASDAQ:GLPG) stock fell ~5% on July 25 after Jefferies Financial downgraded the stock to Underperform from Hold. The firm took the action citing challenges facing the Belgium company's base business and the challenges the biotech faces in rebuilding its pipeline. In an effort to diversify its pipeline the company announced in June the acquisition of CAR-T therapy developer CellPoint, and AboundBio, a company with a fully human antibody-based library. The SA Quant Rating on GLPG is Strong Buy which takes into account factors such as growth and profitability, among others things. Meanwhile, the average Wall Street Analysts' Rating on the stock is Buy, wherein 4 out of 7 analysts give it a Hold, 2 Buy and 1 Strong Buy rating. YTD, Galapagos stock has shed ~5%, better than the broader market indicator SP500TR and several peers. See chart here.
Seeking Alpha • May 19

Galapagos: Can The Company Turn Around?

Amid the biotech bear market, there are companies that are trading on a deep bargain, yet you should be extremely careful before averaging down. Though I noticed the fundamental changes in Galapagos, I gave the company a year to turn around. Here, I presented to you three different scenarios on Galapagos for you to make your own investment decision.
Seeking Alpha • Feb 22

Galapagos: A History Of Disruptive Failures

Galapagos has failed to prove the mettle of its R&D pipeline in most of the programs it ran. Filgotinib's failure was a major disruption. They do have enough cash and a new CEO, so a turnaround may still happen.
Seeking Alpha • Dec 02

Galapagos: The Investment Thesis Is More Appealing Than Ever

Galapagos is in the midst of a transformation process that is expected to result in a completely different company by 2023. Galapagos has over $5.5 billion in cash, an approved drug and a broad pipeline with a market capitalization of only $3.2 billion. Jyseleca is approved in Japan and is expected to generate €500 million annually in sales in Europe in the medium term. Since the stock is trading below liquidation value, it is easy to generate shareholder value with little risk.

Aktionärsrenditen

LKFTUS BiotechsUS Markt
7D4.0%2.9%2.5%
1Y-4.5%33.0%26.4%

Rendite im Vergleich zur Industrie: LKFT unter dem Niveau der Branche US Biotechs , die im vergangenen Jahr eine Rendite von 33% erzielte.

Rendite vs. Markt: LKFT hinter dem Markt US zurück, der im vergangenen Jahr eine Rendite von 26.4 erzielte.

Preisvolatilität

Is LKFT's price volatile compared to industry and market?
LKFT volatility
LKFT Average Weekly Movement4.4%
Biotechs Industry Average Movement10.8%
Market Average Movement7.2%
10% most volatile stocks in US Market16.5%
10% least volatile stocks in US Market3.1%

Stabiler Aktienkurs: LKFT hatte in den letzten 3 Monaten im Vergleich zum US -Markt keine signifikante Preisvolatilität.

Volatilität im Zeitverlauf: LKFTDie wöchentliche Volatilität (4%) ist im vergangenen Jahr stabil geblieben.

Über das Unternehmen

GegründetMitarbeiterCEOWebsite
1999558Henry Gosebruchlakefrontbio.com

Lakefront Biotherapeutics NV, ein Biotechnologieunternehmen, entwickelt Medikamente mit Schwerpunkt Onkologie und Immunologie, vor allem in den Vereinigten Staaten und Europa. Zu den Pipeline-Produkten des Unternehmens gehören GLPG3667, das sich in einer klinischen Phase-2-Studie zur Behandlung von Dermatomyositis und systemischem Lupus erythematodes befindet, GLPG5101, ein CD19-CAR-T-Produktkandidat, der am Point-of-Care hergestellt wird und sich derzeit in einer Phase-1/2-Studie zur Behandlung des rezidivierenden/refraktären Non-Hodgkin-Lymphoms befindet, und GLPG5301, ein BCMA-CAR-T-Produktkandidat, der am Point-of-Care hergestellt wird und sich derzeit in einer Phase-1/2-Studie zur Behandlung des rezidivierenden/refraktären multiplen Myeloms befindet. Das Unternehmen hat Kooperationsvereinbarungen mit Gilead Sciences, Inc. Das Unternehmen war früher unter dem Namen Galapagos NV bekannt und änderte im Mai 2026 seinen Namen in Lakefront Biotherapeutics NV.

Lakefront Biotherapeutics NV's Grundlagenzusammenfassung

Wie verhalten sich die Erträge und Einnahmen von Lakefront Biotherapeutics im Vergleich zum Marktanteil des Unternehmens?
LKFT grundlegende Statistiken
MarktanteilUS$1.83b
Gewinn(TTM)US$567.56m
Umsatz(TTM)US$1.21b
3.2x
Kurs-Gewinn-Verhältnis
1.5x
Kurs-Umsatz-Verhältnis

Ist LKFT zu teuer?

Siehe Fair Value und Bewertungsanalyse

Erträge & Einnahmen

Wichtige Rentabilitätsstatistiken aus dem letzten Ergebnisbericht (TTM)
LKFT Gewinn- und Verlustrechnung (TTM)
Einnahmen€1.04b
Kosten der Einnahmen€328.44m
Bruttogewinn€715.32m
Sonstige Ausgaben€227.38m
Gewinn€487.93m

Zuletzt gemeldete Gewinne

Mar 31, 2026

Datum des nächsten Gewinnberichts

Aug 10, 2026

Gewinn per Aktie (EPS)7.40
Bruttomarge68.53%
Nettogewinnspanne46.75%
Schulden/Eigenkapital-Verhältnis0%

Wie hat sich LKFT auf lange Sicht entwickelt?

Historische Performance und Vergleiche

Unternehmensanalyse und Finanzdaten Status

DatenZuletzt aktualisiert (UTC-Zeit)
Unternehmensanalyse2026/05/26 18:14
Aktienkurs zum Tagesende2026/05/26 00:00
Gewinne2026/03/31
Jährliche Einnahmen2025/12/31

Datenquellen

Die in unserer Unternehmensanalyse verwendeten Daten stammen von S&P Global Market Intelligence LLC. Die folgenden Daten werden in unserem Analysemodell verwendet, um diesen Bericht zu erstellen. Die Daten sind normalisiert, was zu einer Verzögerung bei der Verfügbarkeit der Quelle führen kann.

PaketDatenZeitrahmenBeispiel US-Quelle *
Finanzdaten des Unternehmens10 Jahre
  • Gewinn- und Verlustrechnung
  • Kapitalflussrechnung
  • Bilanz
Konsensschätzungen der Analysten+3 Jahre
  • Finanzielle Vorausschau
  • Kursziele der Analysten
Marktpreise30 Jahre
  • Aktienkurse
  • Dividenden, Splits und Aktionen
Eigentümerschaft10 Jahre
  • Top-Aktionäre
  • Insiderhandel
Verwaltung10 Jahre
  • Das Führungsteam
  • Direktorium
Wichtige Entwicklungen10 Jahre
  • Ankündigungen des Unternehmens

* Beispiel für US-Wertpapiere, für nicht-US-amerikanische Wertpapiere werden gleichwertige regulatorische Formulare und Quellen verwendet.

Sofern nicht anders angegeben, beziehen sich alle Finanzdaten auf einen Jahreszeitraum, werden aber vierteljährlich aktualisiert. Dies wird als Trailing Twelve Month (TTM) oder Last Twelve Month (LTM) Daten bezeichnet. Erfahren Sie mehr.

Analysemodell und Schneeflocke

Einzelheiten zu dem Analysemodell, mit dem dieser Bericht erstellt wurde, finden Sie auf unserer Github-Seite. Außerdem bieten wir Leitfäden zur Verwendung unserer Berichte und Tutorials auf YouTube an.

Erfahren Sie mehr über das Weltklasse-Team, das das Simply Wall St-Analysemodell entworfen und entwickelt hat.

Metriken für Industrie und Sektor

Unsere Branchen- und Sektionskennzahlen werden alle 6 Stunden von Simply Wall St berechnet. Details zu unserem Verfahren finden Sie auf Github.

Analysten-Quellen

Lakefront Biotherapeutics NV wird von 27 Analysten beobachtet. 9 dieser Analysten hat die Umsatz- oder Gewinnschätzungen übermittelt, die als Grundlage für unseren Bericht dienen. Die von den Analysten übermittelten Daten werden im Laufe des Tages aktualisiert.

AnalystEinrichtung
Emily FieldBarclays
Xue ChenBarclays
Patrick TrucchioBerenberg